Pfizer Says Its COVID-19 Pill Paxlovid Fails to Prevent Symptomatic Infection of Household Members
Pfizer announced Friday that a recent large, late-stage trial found that its COVID-19 antiviral pill, Paxlovid, failed at preventing symptomatic infection of people living with a person who has the disease.
The trial enrolled 2,957 participants aged 18 and older who live in the same household as another person who has COVID-19 with symptoms. They were given either Paxlovid or a placebo twice daily for five or 10 days.-- More...
Read Full Article...
Welcome to CFP’s Comment Section!
The Comment section of online publications is the new front in the ongoing Cancel Culture Battle.
Big Tech and Big Media are gunning for the Conservative Voice—through their Comment Sections.
Canada Free Press wishes to stay in the fight, and we want our fans, followers, commenters there with us.
We ask only that commenters keep it civil, keep it clean.
Thank You for your patience and for staying aboard the CFP ‘Mother Ship’.
READ OUR Commenting Policy